Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Identifieur interne : 003557 ( PubMed/Curation ); précédent : 003556; suivant : 003558Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Auteurs : J-J Grob [France] ; M M Amonkar [États-Unis] ; S. Martin-Algarra [Espagne] ; L V Demidov [Russie] ; V. Goodman [États-Unis] ; K. Grotzinger [États-Unis] ; P. Haney [États-Unis] ; E. K Mpgen [Allemagne] ; B. Karaszewska [Pologne] ; C. Mauch [Allemagne] ; W H Miller [Canada] ; M. Millward [Australie] ; B. Mirakhur [États-Unis] ; P. Rutkowski [Pologne] ; V. Chiarion-Sileni [Italie] ; S. Swann [États-Unis] ; A. Hauschild [Allemagne]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Mélanome.
- traitement médicamenteux : Mélanome.
- usage thérapeutique : Antinéoplasiques, Dacarbazine, Imidazoles, Oximes.
- Humains, Métastase tumorale, Qualité de vie.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Dacarbazine, Imidazoles, Oximes.
- drug therapy : Melanoma.
- pathology : Melanoma.
- Humans, Neoplasm Metastasis, Quality of Life.
Abstract
In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial.
DOI: 10.1093/annonc/mdu154
PubMed: 24769640
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003670
Links to Exploration step
pubmed:24769640Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.</title><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="1"><nlm:affiliation>Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Aix-Marseille University, APHM, Hôpital Timone, Marseille</wicri:regionArea></affiliation></author><author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M M" last="Amonkar">M M Amonkar</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S" last="Martin-Algarra">S. Martin-Algarra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona</wicri:regionArea></affiliation></author><author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L V" last="Demidov">L V Demidov</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea></affiliation></author><author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V" last="Goodman">V. Goodman</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K" last="Grotzinger">K. Grotzinger</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P" last="Haney">P. Haney</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E" last="K Mpgen">E. K Mpgen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen</wicri:regionArea></affiliation></author><author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B" last="Karaszewska">B. Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Konin</wicri:regionArea></affiliation></author><author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C" last="Mauch">C. Mauch</name><affiliation wicri:level="1"><nlm:affiliation>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Miller, W H" sort="Miller, W H" uniqKey="Miller W" first="W H" last="Miller">W H Miller</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M" last="Millward">M. Millward</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth</wicri:regionArea></affiliation></author><author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B" last="Mirakhur">B. Mirakhur</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P" last="Rutkowski">P. Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V" last="Chiarion-Sileni">V. Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea></affiliation></author><author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S" last="Swann">S. Swann</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24769640</idno><idno type="pmid">24769640</idno><idno type="doi">10.1093/annonc/mdu154</idno><idno type="wicri:Area/PubMed/Corpus">003670</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003670</idno><idno type="wicri:Area/PubMed/Curation">003557</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.</title><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="1"><nlm:affiliation>Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Aix-Marseille University, APHM, Hôpital Timone, Marseille</wicri:regionArea></affiliation></author><author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M M" last="Amonkar">M M Amonkar</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S" last="Martin-Algarra">S. Martin-Algarra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona</wicri:regionArea></affiliation></author><author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L V" last="Demidov">L V Demidov</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea></affiliation></author><author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V" last="Goodman">V. Goodman</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K" last="Grotzinger">K. Grotzinger</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P" last="Haney">P. Haney</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E" last="K Mpgen">E. K Mpgen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen</wicri:regionArea></affiliation></author><author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B" last="Karaszewska">B. Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Konin</wicri:regionArea></affiliation></author><author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C" last="Mauch">C. Mauch</name><affiliation wicri:level="1"><nlm:affiliation>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Miller, W H" sort="Miller, W H" uniqKey="Miller W" first="W H" last="Miller">W H Miller</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M" last="Millward">M. Millward</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth</wicri:regionArea></affiliation></author><author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B" last="Mirakhur">B. Mirakhur</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P" last="Rutkowski">P. Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V" last="Chiarion-Sileni">V. Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea></affiliation></author><author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S" last="Swann">S. Swann</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Dacarbazine (therapeutic use)</term><term>Humans</term><term>Imidazoles (therapeutic use)</term><term>Melanoma (drug therapy)</term><term>Melanoma (pathology)</term><term>Neoplasm Metastasis</term><term>Oximes (therapeutic use)</term><term>Quality of Life</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Dacarbazine (usage thérapeutique)</term><term>Humains</term><term>Imidazoles (usage thérapeutique)</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (traitement médicamenteux)</term><term>Métastase tumorale</term><term>Oximes (usage thérapeutique)</term><term>Qualité de vie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Dacarbazine</term><term>Imidazoles</term><term>Oximes</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Dacarbazine</term><term>Imidazoles</term><term>Oximes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Neoplasm Metastasis</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Métastase tumorale</term><term>Qualité de vie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24769640</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>27</Day></DateCreated><DateCompleted><Year>2015</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.</ArticleTitle><Pagination><MedlinePgn>1428-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdu154</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient. ClinicalTrials.gov Identifier: NCT01227889.</AbstractText><CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grob</LastName><ForeName>J-J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amonkar</LastName><ForeName>M M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Algarra</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demidov</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grotzinger</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kämpgen</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karaszewska</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Przychodnia Lekarska KOMED, Konin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauch</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>W H</ForeName><Initials>WH</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millward</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirakhur</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkowski</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarion-Sileni</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Collegeville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauschild</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01227889</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>7GR28W0FJI</RegistryNumber><NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>QGP4HA4G1B</RegistryNumber><NameOfSubstance UI="C561627">dabrafenib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Clin Oncol. 2014 Jun;11(6):301</RefSource><PMID Version="1">24840077</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003606" MajorTopicYN="N">Dacarbazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="Y">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRAF</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">dabrafenib</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24769640</ArticleId><ArticleId IdType="pii">mdu154</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdu154</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24769640
|texte= Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24769640" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |